The FDA is considering revisions to the strict "black box" warning on hormone replacement therapy (HRT) for menopausal symptoms. Originally intended to caution against cancer and stroke risks, the warning has significantly reduced HRT prescriptions, leading to undertreatment of debilitating symptoms. Experts argue newer analyses suggest HRT, especially when initiated earlier and via certain delivery methods, may be safe and beneficial. The FDA's planned changes could restore access to this therapy for millions of women.
Prepared by Olivia Bennett and reviewed by editorial team.
Comments